Podcast Episode 115: Repurposing Medications to Slow Progression of PD

PD Library thumbnail

Until the ultimate goal of finding a cure for Parkinson’s disease (PD) is achieved, researchers are taking various approaches to developing a treatment that significantly slows its progression. Here, clinical science and basic science come together to understand the underlying biological mechanisms of PD and then using that knowledge to test medications that target those mechanisms. Having discovered such molecular and cellular malfunctions, scientists may tailor the development of medications to target the underlying causes of the disease.

Another approach has also relied on knowing the mechanisms of the disease but then searching through the vast array of current drugs to treat all sorts of conditions and rationally choosing ones that may work to slow progression of PD – so-called drug repurposing. Dr. Patrik Brundin, Director of the Parkinson’s Disease Center at Van Andel Institute in Grand Rapids, Michigan, explains that this is the approach that the International Linked Clinical Trials (iLCT) program for Parkinson’s has taken. Since its inception in 2010, the iLCT has become one of the most comprehensive drug repurposing programs focused on a single disease. Under this program, seven clinical trials have been completed, and 15 are ongoing, testing 16 potential candidate drugs to slow the progression of PD. The advantage is that the drugs under consideration have already been tested for safety and how they act in the body, speeding up the process of applying them to Parkinson’s.

Download This Episode

Related Resources

About This Episode

Released: October 19, 2021

Headshot of Dr. Patrik Brundin

Patrik Brundin MD, PhD

Deputy Chief Scientific Officer, Van Andel Institute, Director, Center for Parkinson’s Disease, Grand Rapids, MI, USA

Patrik Brundin earned his PhD in 1988 and MD in 1992, both from Lund University, Sweden, and joined the Van Andel Institute in 2012.  He is highly cited in neuroscience with more than 400 publications on Parkinson’s disease and related topics.  His research focuses on pathogenic mechanisms of Parkinson’s and development of therapies that slow or stop disease progression or that repair damaged brain circuits.  He is a member of the World Parkinson Coalition Board of Directors and The Michael J Fox Foundation for Parkinson’s Research Executive Scientific Advisory Board.  He also serves as co-editor-in-chief of the Journal of Parkinson’s Disease and chair of the Linked Clinical Trials scientific committee.

Want More?

Don't forget to subscribe! There are many ways to listen: Apple PodcastsGoogle PlayTuneIn (Amazon Echo), Spotify or RSS Feed. (Need help subscribing? See our quick guide.)

For all of our Substantial Matters podcast episodes, visit parkinson.org/podcast.

X
 

Sign Up for Our E-Newsletter

Get the latest news about PD research, resources and community initiatives – straight to your inbox.

Please enter a valid email

Skip step



Invalid year format. Eg: 2020
Skip step
Skip step


*Please note that not all content is available in both languages. If you are interested in receiving Spanish communications, we recommend selecting “both" to stay best informed on the Foundation's work and the latest in PD news.

Skip step

Thanks for Signing Up

We are proud to have you as a part of our community. To ensure you receive the latest Parkinson’s news, research updates and more, please check your email for a message from us. If you do not see our email, it may be in your spam folder. Just mark as “not spam” and you should receive our emails as expected.

mail icon

Subscribe here to get the latest news on treatments, research and other updates.